Trials / Completed
CompletedNCT00492570
GER-009-06-AVX Early Therapy in Multiple Sclerosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 230 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is being done to increase awareness for early therapy with Avonex for Multiple Sclerosis (MS) and the cognitive dysfunction that accompanies MS, and to record safety data for Avonex.
Detailed description
This study will address the cognitive dysfunction associated with MS. It will track these changes and show that early intervention with Avonex is effective in slowing MS and its effect on patients. Safety data will also be collected during this study.
Conditions
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2007-10-01
- Completion
- 2008-12-01
- First posted
- 2007-06-27
- Last updated
- 2009-06-16
Source: ClinicalTrials.gov record NCT00492570. Inclusion in this directory is not an endorsement.